Bristol-Myers Squibb Company Announces Expiration of Hart-Scott-Rodino Review Period for Acquisition of Medarex, Inc.

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that the Hart-Scott-Rodino (HSR) review period for its tender offer for Medarex, Inc. (NASDAQ: MEDX) has expired.

MORE ON THIS TOPIC